Lululemon is going through leadership drama and a bumpy patch in North America, but the business still throws off plenty of cash and keeps winning abroad. The market seems to be treating it like a brand in long-term decline, and the case here is that this fear may be overdone if the company executes its transition.Read more

Amdocs sits in the plumbing that keeps phone and internet companies running, and it’s shifting from older systems into a more AI‑driven role as the industry moves to the cloud. The big question is whether the market’s recent fear around AI disruption is missing how sticky Amdocs’ customer relationships and recurring work really are.Read more

Many investors worry that new AI tools will make Adobe less important, but the view here is that its software is still deeply embedded in how creatives and marketers work. The case is that the fear is running ahead of reality, while Adobe’s cash-generating engine and “industry standard” status give it time to adapt.Read more

Lululemon’s growth story looks stuck just as shoppers and the market start treating the brand as yesterday’s news, even though the business still throws off a lot of cash and has room to grow outside North America. The key question is whether new leadership can refresh the products and protect the brand’s “cool” before rising competition, tariffs, and discounting do lasting damage.Read more

Paraphrasing Charlie Munger, I would neither buy nor short Tesla, Inc. at present.Read more

Microsoft’s heavy spending is scaring the market, but the real story may be that customers want more cloud and AI capacity than the company can deliver. The bigger question isn’t whether the spending is reckless—it’s what happens if demand cools or regulators step in.Read more

Novo Nordisk’s business model is straightforward. It develops hormone-based therapies, protects them with patents, manufactures them at scale, and sells them at high margins into reimbursed healthcare systems.Read more